Vanguard Fiduciary Trust
CAMP icon

Vanguard Fiduciary Trust’s CAMP4 Therapeutics CAMP Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$988K Buy
226,074
+31,061
+16% +$134K ﹤0.01% 3025
2026
Q1 		$860K Buy
+195,013
New +$926K ﹤0.01% 2989

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust's CAMP Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its CAMP4 Therapeutics (CAMP) stake by 16% in Q2 2026, buying an estimated $134K and bringing the position to 226,074 shares worth $988K. The position accounts for ﹤0.01% of the portfolio, ranked #3025.

Vanguard Fiduciary Trust first reported a position in CAMP in Q1 2026 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Vanguard Fiduciary Trust held 226,074 shares of CAMP4 Therapeutics worth $988K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 31,061 CAMP4 Therapeutics shares in Q2 2026, an estimated $134K.
  • CAMP4 Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3025 holding.
  • Vanguard Fiduciary Trust first reported a position in CAMP4 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.